Novel Blood-Based Biomarkers for HCC

被引：0
作者：
Pai S. [1 ]
Parikh N.D. [1 ,2 ]
机构：
[1] Department of Internal Medicine, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, 48104, MI
[2] Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI
来源：
Current Hepatology Reports | 2024年 / 23卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Biomarkers; Cancer screening; Hepatocellular carcinoma;
D O I：
10.1007/s11901-023-00626-3
中图分类号：
学科分类号：
摘要：
Purpose of Review: Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality. Early detection is crucial for improving patient survival. This review summarizes research on novel biomarkers for HCC, outlining the steps necessary prior to their use in clinical practice. Recent Findings: The most commonly used biomarker used for HCC, alpha-fetoprotein (AFP), has limited sensitivity and specificity for early detection. Recent advances have identified several novel candidates such as AFP-L3, des-gamma carboxyprothrombin (DCP), and cell-free DNA (cfDNA), which can be used independently or incorporated into algorithms such as the GALAD score to improve diagnostic utility. Summary: Validation of reliable novel biomarkers for HCC can improve early detection, and ultimately survival in patients with HCC. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023.
引用
收藏
页码：174 / 184
页数：10
相关论文
共 88 条
  • [1] Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 3, pp. 209-249, (2021)
  • [2] Fattovich G., Stroffolini T., Zagni I., Donato F., Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, 127, 5 Suppl 1, pp. S35-S50, (2004)
  • [3] Marrero J.A., Kulik L.M., Sirlin C.B., Zhu A.X., Finn R.S., Abecassis M.M., Et al., Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases, Hepatology, 68, 2, pp. 723-750, (2018)
  • [4] Maucort-Boulch D., de Martel C., Franceschi S., Plummer M., Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide, Int J Cancer, 142, 12, pp. 2471-2477, (2018)
  • [5] Kabbany M.N., Conjeevaram Selvakumar P.K., Watt K., Lopez R., Akras Z., Zein N., Et al., Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey Data, Am J Gastroenterol, 112, 4, pp. 581-587, (2017)
  • [6] Zhai M., Liu Z., Long J., Zhou Q., Yang L., Liu S., Et al., The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017, Sci Rep, 11, 1, (2021)
  • [7] Parikh N.D., Tayob N., Singal A.G., Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era?, J Hepatol, 78, 1, pp. 207-216, (2023)
  • [8] Zhang X., El-Serag H.B., Thrift A.P., Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare, Cancer Causes Control, 32, 4, pp. 317-325, (2021)
  • [9] Zhang B.H., Yang B.H., Tang Z.Y., Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol, 130, 7, pp. 417-422, (2004)
  • [10] Arnold M., Abnet C.C., Neale R.E., Vignat J., Giovannucci E.L., McGlynn K.A., Et al., Global burden of 5 major types of gastrointestinal cancer, Gastroenterology, 159, 1, (2020)
123456789